Beyond Rest & Fluids: How IV Vitamin C and Glutathione May Accelerate Recovery from Glandular Fever
A research-backed look at intravenous nutrient therapies and their potential role in combating Epstein-Barr virus, reducing viral load, and restoring immune function.Glandular fever — known clinically as infectious mononucleosis — can leave people bedridden for weeks, with a crushing fatigue that can linger for months or even years. Conventional medicine offers rest, hydration, and time. But a growing body of research suggests that intravenous (IV) vitamin C and IV glutathione may offer something more: a targeted antiviral and antioxidant intervention that supports the immune system exactly when it needs it most.
Understanding Glandular Fever and the Epstein-Barr Virus
Glandular fever is caused by the Epstein-Barr virus (EBV), a member of the herpesvirus family. EBV is extraordinarily widespread — infecting more than 90% of the global adult population. For most people, initial infection occurs in childhood and causes little more than a mild cold. But when infection occurs in adolescence or adulthood, it frequently manifests as infectious mononucleosis: the classic syndrome of extreme fatigue, sore throat, swollen lymph nodes, and fever that can persist for six weeks or longer.
More concerning is what happens after the acute phase. EBV does not leave the body; it establishes lifelong latency in B lymphocytes. In some individuals — particularly those with compromised immune function, high oxidative stress, or nutritional deficiencies — the virus can reactivate repeatedly, driving chronic fatigue syndromes and long-term immune dysfunction.
EBV and Chronic Fatigue Syndrome
EBV infection is one of the most common triggers of Chronic Fatigue Syndrome (ME/CFS). Research has identified a deficient EBV-specific B- and T-cell response in many CFS patients, with up to 76% showing diminished or absent EBV-specific memory B cells — a marker of impaired immune control over the virus (Lünemann et al., 2014).
There is no approved antiviral medication or vaccine for EBV. Standard care remains supportive. This gap is precisely where intravenous nutritional therapies have attracted scientific attention.
Intravenous Vitamin C: Why the Delivery Route Matters
Vitamin C (ascorbic acid) is perhaps the most well-studied nutritional immune support agent in the scientific literature. But there is a critical distinction between oral vitamin C and intravenous vitamin C that most people are not aware of.
The gastrointestinal tract tightly regulates how much vitamin C is absorbed. Even at high oral doses, plasma concentrations are capped at around 70–80 micromoles per litre (µmol/L). Intravenous administration completely bypasses this limitation. Infusions of 7.5 to 50 grams can achieve plasma concentrations of 10,000 µmol/L — over 100 times higher than oral dosing can achieve. These are described as "pharmacologic" concentrations, and it is at these levels that vitamin C begins to behave as a potent antiviral and pro-oxidant therapeutic agent.
"Pharmacologic plasma ascorbate concentrations achieved by intravenous infusion have been linked with benefits to endothelial function, cellular immune function, antioxidative capacity, pain relief, and treatment of cancer and other illnesses."
Riordan Clinic Research Institute, published in Medical Science Monitor
The Evidence: IV Vitamin C Against EBV
The most significant clinical evidence for IV vitamin C in EBV infection comes from a landmark study conducted at the Riordan Clinic in the United States, published in the peer-reviewed journal Medical Science Monitor in 2014 and subsequently indexed in PubMed.
The Riordan Clinic Study (Mikirova et al., 2014)
Researchers examined data from 178 patients with elevated EBV Early Antigen IgG antibodies and 40 patients with elevated EBV Viral Capsid Antigen (VCA) IgM antibodies — markers indicating active or recent EBV infection. Most had diagnoses of chronic fatigue syndrome, infectious mononucleosis, or general EBV infection. Patients received IV vitamin C infusions ranging from 7.5 to 50 grams.
Finding 01
Reduced Viral Antibody Levels
Patients receiving five or more IV vitamin C treatments showed an average 46% decrease in EBV antibody levels, compared to just 17% in untreated controls — a statistically significant difference (p<0.002).
Finding 02
Inverse Antibody Correlation
A direct inverse correlation was found between plasma vitamin C concentrations and EBV VCA IgM antibody levels: higher vitamin C = lower viral antigen load during the acute phase of disease.
Finding 03
Disease Duration Effect
High-dose IV vitamin C therapy showed a positive effect on disease duration — suggesting faster resolution of the acute infection when treatment was initiated.
Finding 04
Vitamin C Depletion Confirmed
The study confirmed that EBV infection dramatically depletes the body's vitamin C stores — meaning supplementation restores a critical antioxidant defence at exactly the right time.
This finding was further supported by a review published in the journal Life (MDPI, 2021), which confirmed that in the 178-patient cohort, "patients with high levels of vitamin C had lower levels of antigens in the acute state of disease" — reinforcing the direct antiviral relevance of restoring plasma ascorbate during EBV infection.
How Vitamin C Fights Viruses: The Mechanisms
The antiviral effects of high-dose vitamin C are not simply about immune "boosting." Several distinct biological mechanisms have been identified:
1. Interferon Stimulation
Vitamin C promotes the production of interferons — naturally occurring antiviral proteins that the immune system deploys as a first-line defence. Research by Kim et al. (2013), published in Immune Network, demonstrated that vitamin C is essential for the production of interferon-alpha/beta at the initial stage of viral infection. Mice deficient in vitamin C showed significantly increased viral loads and reduced interferon production. Additionally, in vitro studies confirmed that in the presence of ascorbic acid combined with glutathione, interferon production is directly stimulated.
2. Direct Inhibition of Viral Replication
In vitro studies have shown that millimolar concentrations of ascorbate — concentrations only achievable through IV administration — directly hinder viral infection and replication. The Riordan Clinic researchers noted that their clinical findings were consistent with these laboratory findings, showing "reduction in viral load levels over time during IV vitamin C therapy."
3. Natural Killer Cell Activation
Vitamin C enhances natural killer (NK) cell activity — specialised immune cells that identify and destroy virus-infected cells. NK cell function is known to be suppressed during active EBV infection, and vitamin C's role in NK cell stimulation provides another mechanism of action for IV therapy.
4. Neutralising Oxidative Stress
Viral infections generate significant oxidative stress — a damaging imbalance between free radicals and antioxidant defences. Ascorbate's powerful antioxidant capacity helps neutralise this reactive oxygen species (ROS) damage, creating a cellular environment less hospitable to viral replication and more conducive to tissue repair.
IV Glutathione: The Master Antioxidant in EBV Recovery
While IV vitamin C has attracted the most direct EBV-specific research, IV glutathione plays an equally important — and complementary — role in recovering from glandular fever. Glutathione (GSH) is the body's most abundant endogenous antioxidant, present in virtually every cell. Its role in viral infections is only now being fully appreciated.
EBV Actively Disrupts Glutathione Balance
Research published in PLOS Pathogens (Lünemann et al., 2022) revealed a striking finding: EBV infection upregulates the glutamate transporter EAAT3 as a mechanism to maintain the redox homeostasis of infected cells. In other words, the virus has evolved a strategy to manipulate the host's glutathione system for its own survival — an adaptation to protect EBV-infected cells against the virus-induced oxidative stress.
Furthermore, a 2020 study published in Theranostics (Hu et al.) found that EBV's oncoprotein LMP1 mediates high oxidative stress, which in turn drives EBV lytic reactivation — the cycle in which latent EBV "wakes up" and replicates. This means oxidative stress is not just a side effect of EBV infection; it is a driver of viral reactivation. Restoring glutathione levels directly targets this mechanism.
⚡
Antioxidants May Prevent EBV Reactivation
Research highlighted by Simmaron Research noted that "high rates of oxidative stress can reactivate EBV and that antioxidants — including NAC, catalase, and L-glutathione — might be helpful in reducing EBV reactivation." This is particularly relevant for those with chronic or relapsing EBV-related fatigue syndromes, where oxidative stress is consistently elevated.
Glutathione's Direct Antiviral Activity
Beyond EBV specifically, there is compelling evidence for glutathione's direct antiviral activity against herpesviruses. A landmark study in Antiviral Research (Palamara et al., 1995) found that glutathione inhibited herpes simplex virus type 1 (HSV-1) replication by more than 99% in vitro. Crucially, intracellular glutathione levels dropped dramatically within the first 24 hours of viral exposure — and replenishing GSH not only restored those levels but also inhibited viral replication even when added 24 hours after infection was established. EBV, like HSV-1, is a member of the herpesvirus family, and this antiviral mechanism is considered broadly applicable across the family.
Glutathione and Immune Cell Function
Glutathione is critical for the optimal function of T lymphocytes and other immune cells that are responsible for controlling EBV. During active infection, immune cells experience high metabolic demand and oxidative stress. Depleted glutathione in these cells directly impairs their ability to mount an effective antiviral response. IV administration of glutathione bypasses the poor oral bioavailability of the supplement and rapidly restores intracellular levels in immune cells.
The Vitamin C–Glutathione Synergy
One of the most exciting aspects of combining IV vitamin C with IV glutathione is their synergistic relationship. Vitamin C regenerates oxidised glutathione back to its active reduced form (GSH), extending its effective lifespan in the body. In turn, glutathione helps recycle oxidised vitamin C. Research published in Life (MDPI, 2021) confirmed that "in the presence of ascorbic acid plus glutathione, interferon was produced" — suggesting the combination produces antiviral effects greater than either alone. In clinical IV therapy, these two agents are therefore often administered together or in close sequence to maximise this recycling loop.
The Role of Vitamin D
The Riordan Clinic research also identified a notable secondary finding: vitamin D concentrations correlated with EBV Early Antigen IgG antibody levels. Higher vitamin D was associated with lower EBV antibody levels, consistent with vitamin D's known role in modulating both innate and adaptive immune responses. Many IV nutrient protocols for EBV recovery therefore incorporate vitamin D assessment and optimisation alongside vitamin C and glutathione.
Who May Benefit Most?
IV vitamin C and glutathione therapy is worth considering in several EBV-related clinical scenarios:
Acute glandular fever — particularly where symptoms are severe, prolonged, or not improving within expected timeframes. Early intervention with IV vitamin C may reduce viral antibody levels and shorten disease duration.
Post-viral fatigue — for those who have "recovered" from glandular fever but continue to experience debilitating fatigue weeks or months later. Addressing oxidative stress and immune dysfunction with IV glutathione and vitamin C may support resolution of this post-viral syndrome.
Chronic or reactivating EBV — individuals with a history of glandular fever who experience recurrent fatigue, swollen glands, or persistent elevated EBV antibodies may benefit from ongoing IV nutrient support as part of a comprehensive integrative protocol.
Safety Considerations
High-dose IV vitamin C is generally well-tolerated. However, it is contraindicated in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as high-dose ascorbate can trigger haemolysis in these patients. G6PD testing is a standard pre-treatment screening step at reputable IV clinics. Caution is also advised in those with kidney disease or a history of calcium oxalate kidney stones.
IV glutathione is considered safe for most individuals, with a strong tolerability profile in the existing literature. As with any IV therapy, treatments should be administered by trained healthcare professionals in a clinical setting.
References
Mikirova N, Hunninghake R.Effect of high dose vitamin C on Epstein-Barr viral infection.Medical Science Monitor. 2014;20:725–732.PubMed: 24793092
Riordan Clinic Research Institute.Research study shows high dose vitamin C as a viable treatment for Epstein-Barr viral infection.PR Newswire, 2018.riordanclinic.org
Vollbracht C, Kraft K.The Effects of Vitamin C on the Multiple Pathophysiological Stages of COVID-19.Life (MDPI). 2021;11(12):1341. doi:10.3390/life11121341
Kim Y, Kim H, Bae S, et al.Vitamin C is an essential factor on the anti-viral immune response through the production of interferon-α/β at the initial stage of influenza A virus (H3N2) infection.Immune Network. 2013;13(2):70–74.
Palamara AT, et al.Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication.Antiviral Research. 1995;27(3):237–253. ScienceDirect.
Lünemann JD, et al.Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome.PLOS Pathogens. 2014. PMC3893202.
Lunemann / Rowe et al.Epstein-Barr virus infection controls the concentration of the intracellular antioxidant glutathione by upregulation of the glutamate transporter EAAT3 in tumor cells.PubMed. 2022.PMID: 36344769
Hu J, Li Y, Li H, et al.Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.Theranostics. 2020;10(26):11921–11937. PMC7667690.
Strycharz-Dudziak M, et al.Total Antioxidant Status (TAS), Superoxide Dismutase (SOD), and Glutathione Peroxidase (GPx) in Oropharyngeal Cancer Associated with EBV Infection.Oxidative Medicine and Cellular Longevity. 2019. PMC6644273.
Simmaron Research.EBV I: A Deficient Immune Response — Increased Levels of EBV Opens Up EBV Question in CFS.2014. simmaronresearch.com
Carr AC, Maggini S.Vitamin C and Immune Function.Nutrients. 2017;9(11):1211.
Siegel BV, Morton JI.Vitamin C and Immunity: Natural Killer (NK) cell factor.International Journal of Vitamin and Nutrition Research. 1983;53:179–183.
Medical Disclaimer: This article is for informational and educational purposes only. It is not intended to constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting any IV therapy or treatment protocol, particularly if you have pre-existing health conditions. IV vitamin C is contraindicated in G6PD deficiency. Testing and clinical screening should always precede treatment.
